Literature DB >> 23810224

Next steps for research on hormonal contraception and HIV.

Lauren J Ralph1, Sandra I McCoy, Timothy Hallett, Nancy Padian.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23810224     DOI: 10.1016/S0140-6736(13)61420-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

2.  Hormonal contraceptive methods and HIV: research gaps and programmatic priorities.

Authors:  Halley E M Riley; Petrus S Steyn; Sharon L Achilles; Emily Bass; Andrew L Gray; Chelsea B Polis; James N Kiarie
Journal:  Contraception       Date:  2017-06-07       Impact factor: 3.375

3.  The Need for Policy Change Regarding Progestin-Only Injectable Contraceptives.

Authors:  Erica L Gollub; Heidi E Jones; Lauren J Ralph; Janneke H H M van de Wijgert; Nancy Padian; Zena Stein
Journal:  J Womens Health (Larchmt)       Date:  2018-12-21       Impact factor: 3.017

4.  Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study).

Authors:  G Justus Hofmeyr; Charles S Morrison; Jared M Baeten; Tsungai Chipato; Deborah Donnell; Peter Gichangi; Nelly Mugo; Kavita Nanda; Helen Rees; Petrus Steyn; Douglas Taylor
Journal:  Gates Open Res       Date:  2018-03-13

5.  Cervical cancer precursors and hormonal contraceptive use in HIV-positive women: application of a causal model and semi-parametric estimation methods.

Authors:  Hannah H Leslie; Deborah A Karasek; Laura F Harris; Emily Chang; Naila Abdulrahim; May Maloba; Megan J Huchko
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

6.  Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.

Authors:  Angela M Crook; Deborah Ford; Mitzy Gafos; Richard Hayes; Anatoli Kamali; Saidi Kapiga; Andrew Nunn; Maureen Chisembele; Gita Ramjee; Helen Rees; Sheena McCormack
Journal:  Hum Reprod       Date:  2014-05-16       Impact factor: 6.918

7.  Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.

Authors:  N E Quispe Calla; R D Vicetti Miguel; P N Boyaka; L Hall-Stoodley; B Kaur; W Trout; S D Pavelko; T L Cherpes
Journal:  Mucosal Immunol       Date:  2016-03-23       Impact factor: 7.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.